 1994 Cordis receives FDA-approval for the first bare-metal stent in the US, the PALMAZ-SCHATZ® Balloon-Expandable Stent for coronary artery applications.1996 Cordis joins the Johnson & Johnson interventional business called “Johnson & Johnson Intervention Systems (JJIS)” and forms Cordis Corporation.In 1997 Cordis Corporation expanded into the rapidly growing field of electrophysiology through the acquisition of Biosense Inc. One year later, in 1998, Biosense Inc. merged with Webster Laboratories to form Biosense Webster, Inc.

2002 The CYPHER® Sirolimus-eluting Coronary Stent, the first drug-eluting stent for patients with coronary heart disease is approved for use in the EU.